Hyper Insight™ – Infarct
Hyper Insight™ Stroke AI
One platform across the stroke pathway — hemorrhage, infarction, aneurysm, perfusion and 3D vascular imaging, on CT and MR. One solution is FDA-cleared today; seven more are in the FDA process. Select any solution for its description, capabilities, and performance evidence.
Hyper Insight™ – Infarct
NCCTLaunched · KRMFDS ApprovedFDA in ProgressPre-FDA Access
Detects and localizes suspected acute cerebral infarction on non-contrast brain CT — including LVO, MeVO and SVO — with probability scores and ROI visualization.
Capabilities
- Precise & comprehensive AI detection — highlights suspicious regions and assigns probability scores
- AI-powered stroke detection (LVO / MeVO / SVO)
- Detects small, subtle and posterior-circulation infarcts
- AI probability mapping
- Intuitive reporting
NCCTAcute Infarct DetectionLocalizationProbability ScoresROI VisualizationASPECTSReportMobile Alert & DICOM Viewer
Click to zoomPerformance & evidence
Multi-center, retrospective, crossover, randomized superiority study — brain CTs from 917 patients (367 infarction, 550 normal); nine reviewers across three expertise tiers.
Sens 88.9% · Spec 91.4%
AI sensitivity by volume
≥10 cc 79.0% · ≥20 cc 84.8% · ≥30 cc 88.9%
⚠ Latest internal validation results
What it means clinically
- Among 9 readers of varying experience, AI assistance significantly improved accuracy +3.60%, sensitivity +4.26% and specificity +3.15%. (Scientific Reports 2026, N=917)
- Non-radiologist physicians, such as those in underserved regions, showed the largest accuracy improvement +5.38% and the largest sensitivity benefit +7.27%.
- AI assistance significantly improved sensitivity for lesions under 5 mL +4.04% — the most challenging and most frequently missed NCCT infarct category — as well as 5–10 mL +7.84% and above 50 mL +11.11%.